SG10201906329VA - Prohemostatic proteins for the treatment of bleeding - Google Patents

Prohemostatic proteins for the treatment of bleeding

Info

Publication number
SG10201906329VA
SG10201906329VA SG10201906329VA SG10201906329VA SG10201906329VA SG 10201906329V A SG10201906329V A SG 10201906329VA SG 10201906329V A SG10201906329V A SG 10201906329VA SG 10201906329V A SG10201906329V A SG 10201906329VA SG 10201906329V A SG10201906329V A SG 10201906329VA
Authority
SG
Singapore
Prior art keywords
bleeding
treatment
proteins
prohemostatic
subject
Prior art date
Application number
SG10201906329VA
Other languages
English (en)
Inventor
Daniël Verhoef
Pieter H Reitsma
Mettine H A Bos
Original Assignee
Academisch Ziekenhuis Leiden
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Academisch Ziekenhuis Leiden filed Critical Academisch Ziekenhuis Leiden
Publication of SG10201906329VA publication Critical patent/SG10201906329VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6432—Coagulation factor Xa (3.4.21.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21006—Coagulation factor Xa (3.4.21.6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SG10201906329VA 2014-05-26 2015-05-26 Prohemostatic proteins for the treatment of bleeding SG10201906329VA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14169895 2014-05-26

Publications (1)

Publication Number Publication Date
SG10201906329VA true SG10201906329VA (en) 2019-08-27

Family

ID=50774744

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201906329VA SG10201906329VA (en) 2014-05-26 2015-05-26 Prohemostatic proteins for the treatment of bleeding
SG11201609811TA SG11201609811TA (en) 2014-05-26 2015-05-26 Prohemostatic proteins for the treatment of bleeding

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201609811TA SG11201609811TA (en) 2014-05-26 2015-05-26 Prohemostatic proteins for the treatment of bleeding

Country Status (25)

Country Link
US (4) US10537618B2 (ja)
EP (2) EP3149163B1 (ja)
JP (3) JP6640198B2 (ja)
KR (2) KR102351728B1 (ja)
CN (1) CN106536566A (ja)
AU (2) AU2015268149B2 (ja)
BR (1) BR112016027649A2 (ja)
CA (1) CA2949349A1 (ja)
DK (1) DK3149163T3 (ja)
EA (2) EA037991B1 (ja)
ES (1) ES2813440T3 (ja)
HR (1) HRP20201311T1 (ja)
HU (1) HUE052098T2 (ja)
IL (2) IL249132B (ja)
LT (1) LT3149163T (ja)
MA (2) MA51688A (ja)
MX (2) MX2016015567A (ja)
NZ (1) NZ727444A (ja)
PL (1) PL3149163T3 (ja)
PT (1) PT3149163T (ja)
RS (1) RS60706B1 (ja)
SG (2) SG10201906329VA (ja)
SI (1) SI3149163T1 (ja)
WO (1) WO2015183085A1 (ja)
ZA (1) ZA201608017B (ja)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015183085A1 (en) 2014-05-26 2015-12-03 Academisch Ziekenhuis Leiden Prohemostatic proteins for the treatment of bleeding
CN108486197B (zh) * 2018-03-06 2021-10-22 爱斯特（成都）生物制药股份有限公司 高纯度依度沙班中间体的制备方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4703004A (en) 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide
ATE158816T1 (de) 1990-11-26 1997-10-15 Genetics Inst Expression von pace in wirtszellen und verfahren zu dessen verwendung
US6797492B2 (en) 1991-05-17 2004-09-28 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
DE4203965A1 (de) 1992-02-11 1993-08-12 Max Planck Gesellschaft Antidot fuer hirudin und synthetische thrombininhibitoren
AT404357B (de) 1995-06-13 1998-11-25 Immuno Ag Prothrombin-derivate
DE19605126A1 (de) 1996-02-12 1997-08-14 Basf Ag Thrombinmuteine als Antidot für Thrombininhibitoren
US6200955B1 (en) 1996-06-11 2001-03-13 Commonwealth Biotechnologies, Inc. Heparin binding peptides
US6624141B1 (en) 1999-03-17 2003-09-23 The Regents Of The University Of Michigan Protamine fragment compositions and methods of use
EP1728798A1 (en) 2005-06-01 2006-12-06 ZLB Behring GmbH Coagulation factor X polypeptides with modified activation properties
MX336958B (es) * 2005-11-15 2016-02-05 Philadelphia Children Hospital Metodos y composiciones para modular la hemostasia.
EP1820508A1 (en) * 2006-02-21 2007-08-22 CSL Behring GmbH Coagulation factor X polypeptides with modified activation properties
PL2147096T3 (pl) * 2007-04-13 2015-08-31 Catalyst Biosciences Inc Zmodyfikowane polipeptydy czynnika VII i ich zastosowania
PL3078743T3 (pl) 2007-09-28 2020-11-02 Portola Pharmaceuticals, Inc. Antidotum dla inhibitorów czynnika XA i sposoby ich stosowania
TWI538916B (zh) * 2008-04-11 2016-06-21 介控生化科技公司 經修飾的因子vii多肽和其用途
US9056106B2 (en) 2009-07-15 2015-06-16 Portola Pharmaceuticals, Inc. Unit dose formulation of antidotes for factor Xa inhibitors and methods of using the same
WO2014018120A1 (en) 2012-07-25 2014-01-30 Catalyst Biosciences, Inc. Modified factor x polypeptides and uses thereof
ES2761730T3 (es) 2013-01-31 2020-05-20 Pfizer Composiciones y procedimientos para contrarrestar la inhibición del factor Xa
US10119101B2 (en) 2014-04-28 2018-11-06 Ecolab Usa Inc. Method of minimizing enzyme based aerosol mist using a pressure spray system
WO2015183085A1 (en) * 2014-05-26 2015-12-03 Academisch Ziekenhuis Leiden Prohemostatic proteins for the treatment of bleeding

Also Published As

Publication number Publication date
EA201692161A1 (ru) 2017-08-31
MA40042B1 (fr) 2020-08-31
PT3149163T (pt) 2020-09-03
EA037991B1 (ru) 2021-06-21
US20170157223A1 (en) 2017-06-08
AU2021203838A1 (en) 2021-07-08
MX2020013410A (es) 2021-02-26
EP3149163B1 (en) 2020-06-03
JP6640198B2 (ja) 2020-02-05
ES2813440T3 (es) 2021-03-23
IL277377B (en) 2021-10-31
SI3149163T1 (sl) 2020-10-30
KR102245264B1 (ko) 2021-04-28
US11304995B2 (en) 2022-04-19
HUE052098T2 (hu) 2021-04-28
EP3744840A1 (en) 2020-12-02
RS60706B1 (sr) 2020-09-30
IL277377A (en) 2020-11-30
MX2016015567A (es) 2017-06-29
SG11201609811TA (en) 2016-12-29
US11357836B2 (en) 2022-06-14
AU2015268149A1 (en) 2016-12-08
JP2020062039A (ja) 2020-04-23
JP2017522900A (ja) 2017-08-17
EA202190813A1 (ru) 2021-12-31
ZA201608017B (en) 2019-04-24
WO2015183085A1 (en) 2015-12-03
US20220288172A1 (en) 2022-09-15
US20200138916A1 (en) 2020-05-07
DK3149163T3 (da) 2020-08-31
US10537618B2 (en) 2020-01-21
AU2021203838B2 (en) 2023-03-02
IL249132A0 (en) 2017-01-31
LT3149163T (lt) 2020-09-25
CA2949349A1 (en) 2015-12-03
KR20170020332A (ko) 2017-02-22
KR20210054573A (ko) 2021-05-13
BR112016027649A2 (pt) 2017-08-15
AU2015268149B2 (en) 2021-03-11
NZ727444A (en) 2021-12-24
MA51688A (fr) 2020-12-02
JP2022134139A (ja) 2022-09-14
KR102351728B1 (ko) 2022-01-14
EP3149163A1 (en) 2017-04-05
CN106536566A (zh) 2017-03-22
HRP20201311T1 (hr) 2020-12-11
PL3149163T3 (pl) 2020-12-28
US20200138917A1 (en) 2020-05-07
IL249132B (en) 2020-09-30

Similar Documents

Publication Publication Date Title
PH12018500057A1 (en) Substituted oxopyridine derivatives
MX2018007703A (es) Inhibidores de la interaccion de menina-linaje leucemico mixto.
MY182667A (en) Food compositions comprising one or both of recombinant beta-lactoglobulin protein and recombinant alphalactalbumin protein
WO2017015622A3 (en) Gdf11 binding proteins and uses thereof
EP3267792A4 (en) Compositions for use in treating pulmonary arterial hypertension
MX2017010673A (es) Heterociclos biciclicos como inhibidores de receptores del factor de crecimiento fibroblastico (fgfr).
MX2021013665A (es) Proteinas de union a calicreina en plasma y usos de las mismas para tratar el angioedema hereditario.
EA201791775A1 (ru) Цистеиновая протеаза
MX2017016345A (es) Proteinas de fusion para inhibir la angiogenesis.
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA202090632A1 (ru) Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
EA201692552A1 (ru) МОДИФИЦИРОВАННЫЕ МЕНИНГОКОККОВЫЕ ПОЛИПЕПТИДЫ fHbp
SI3197472T1 (sl) Rekombinantni proteini brez PHE za uporabo pri zdravljenju fenilketonurije
EA201790380A1 (ru) Ингибиторы mk2 и их применения
EA201691429A1 (ru) МОДИФИЦИРОВАННЫЕ МЕНИНГОКОККОВЫЕ ПОЛИПЕПТИДЫ fHbp
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
MX2017006019A (es) Apilimod para uso en el tratamiento de melanoma.
WO2016007540A3 (en) Compositions and methods for treating dengue virus infection
MX2015008310A (es) Procedimiento para el tratamiento de enfermedades relacionadas con el factor inducible por hipoxia (hif) -.
MX2020013410A (es) Proteinas prohemostaticas para el tratamiento de hemorragias.
MX2018007468A (es) Composiciones de colageno 7 y metodos para usar las mismas.
PH12016501608A1 (en) Peptides and methods of use
WO2016025533A3 (en) Compositions and methods for treating synucleinopathies
WO2015191636A3 (en) Xanthine oxidase inhibitors and methods of use
MX2018006479A (es) Serinas proteasas recombinantes.